Nuveen Asset Management, LLC Hookipa Pharma Inc. Transaction History

Nuveen Asset Management, LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$1.33 - $2.31 $174,191 - $302,543	-130,971 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$1.26 - $2.52 $44,440 - $88,880	-35,270 Reduced 21.22%	130,971 $212,000
Q4 2021 Feb 14, 2022	SELL	$2.33 - $5.94 $11,834 - $30,169	-5,079 Reduced 2.96%	166,241 $427,000
Q3 2021 Nov 12, 2021	SELL	$5.89 - $9.35 $7,079 - $11,238	-1,202 Reduced 0.7%	171,320 $1.16 Million
Q2 2021 Aug 16, 2021	BUY	$9.16 - $19.51 $939,715 - $2 Million	102,589 Added 146.7%	172,522 $1.58 Million
Q1 2021 May 17, 2021	BUY	$10.64 - $14.7 $195,541 - $270,156	18,378 Added 35.65%	69,933 $941,000
Q4 2020 Feb 16, 2021	SELL	$9.32 - $13.63 $74,224 - $108,549	-7,964 Reduced 13.38%	51,555 $572,000
Q3 2020 Nov 16, 2020	SELL	$8.59 - $11.89 $59,313 - $82,100	-6,905 Reduced 10.4%	59,519 $563,000
Q2 2020 Aug 14, 2020	BUY	$7.23 - $12.1 $194,631 - $325,732	26,920 Added 68.14%	66,424 $772,000
Q1 2020 May 14, 2020	BUY	$5.9 - $13.8 $168,214 - $393,451	28,511 Added 259.36%	39,504 $325,000
Q3 2019 Nov 14, 2019	BUY	$6.45 - $8.44 $70,904 - $92,780	10,993 New	10,993 $82,000

677K

Ticker HOOK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 51,654,500
Market Cap $173M
Description
HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase II clinical trial in patients awaiting kidney transpl...

Get notified when there are updates to the investment portfolio of Nuveen Asset Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Nuveen Asset Management, LLC with notifications on news.